CRISPR-Cas9-mediated disruption of the GATA1 binding site on DHS +58 selectively decreased BCL11A expression in erythrocytes leading to increased HbF levels and improved phenotype of SCD HSPCs-derived erythrocytes. The gene discussed is BCL11A; the disease is Schnyder corneal dystrophy.